Imaging Advances in the Management of Kidney Cancer

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2018 Oct 30

PMID 30372386

Citations 10

Authors

Katherine M Krajewski

Ivan Pedrosa

Affiliations

Soon will be listed here.

Abstract

New developments in cross-sectional imaging, including contrast-enhanced ultrasound, dual-energy computed tomography, multiparametric magnetic resonance imaging, single-photon emission computed tomography, and positron emission tomography, together with novel application of existing and novel radiotracers, have changed the landscape of renal mass characterization (ie, virtual biopsy) as well as the detection of metastatic disease, prognostication, and response assessment in patients with advanced kidney cancer. A host of imaging response criteria have been developed to characterize the response to targeted and immune therapies and correlate with patient outcomes, each with strengths and limitations. Recent efforts to advance the field are aimed at increasing objectivity with quantitative techniques and the use of banks of imaging data to match the vast genomic data that are becoming available. The emerging field of radiogenomics has the potential to transform further the role of imaging in kidney cancer management through eventual noninvasive characterization of the tumor histology and genetic microenvironment in single renal masses and/or metastatic disease. We review of the effect of currently available imaging techniques in the management of patients with kidney cancer, including localized, locally advanced, and metastatic disease.

Citing Articles

Cancer Incidence Trends in Successive Social Generations in the US.

Rosenberg P, Miranda-Filho A JAMA Netw Open. 2024; 7(6):e2415731.

PMID: 38857048 PMC: 11165384. DOI: 10.1001/jamanetworkopen.2024.15731.

Kidney Cancer Incidence among Non-Hispanic American Indian and Alaska Native Populations in the United States, 1999 to 2020.

Melkonian S, Jim M, Haverkamp D, Lee M, Janitz A, Campbell J Cancer Epidemiol Biomarkers Prev. 2024; 33(8):1065-1072.

PMID: 38727561 PMC: 11293958. DOI: 10.1158/1055-9965.EPI-24-0179.

Disparities in Trend of Renal Cell Carcinoma Mortality in the United States.

Doddi S, Rashid M Cancer Diagn Progn. 2024; 4(3):256-263.

PMID: 38707733 PMC: 11062163. DOI: 10.21873/cdp.10317.

Patient-specific, deliverable, and self-expandable surgical guide development and evaluation using 4D printing for laparoscopic partial nephrectomy.

Ock J, Gwon E, Kim T, On S, Moon S, Kyung Y Sci Rep. 2024; 14(1):5722.

PMID: 38459159 PMC: 10924080. DOI: 10.1038/s41598-024-56075-5.

Polarization-sensitive optical coherence tomography for renal tumor detection in human kidneys.

Yan F, Wang C, Yan Y, Zhang Q, Yu Z, Patel S Opt Lasers Eng. 2023; 173.

PMID: 37982078 PMC: 10653339. DOI: 10.1016/j.optlaseng.2023.107900.

References

Chandrasekar T, Ahmad A, Fadaak K, Jhaveri K, Bhatt J, Jewett M . Natural History of Complex Renal Cysts: Clinical Evidence Supporting Active Surveillance. J Urol. 2017; 199(3):633-640. DOI: 10.1016/j.juro.2017.09.078. View

Dodelzon K, Mussi T, Babb J, Taneja S, Rosenkrantz A . Prediction of growth rate of solid renal masses: utility of MR imaging features--preliminary experience. Radiology. 2012; 262(3):884-93. DOI: 10.1148/radiol.11111074. View

Gorin M, Rowe S, Baras A, Solnes L, Ball M, Pierorazio P . Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. Eur Urol. 2015; 69(3):413-6. DOI: 10.1016/j.eururo.2015.08.056. View

Pedrosa I, Chou M, Ngo L, Baroni R, Genega E, Galaburda L . MR classification of renal masses with pathologic correlation. Eur Radiol. 2007; 18(2):365-75. DOI: 10.1007/s00330-007-0757-0. View

Choueiri T, Escudier B, Powles T, Mainwaring P, Rini B, Donskov F . Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1814-23. PMC: 5024539. DOI: 10.1056/NEJMoa1510016. View

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

Gayed B, Youssef R, Darwish O, Kapur P, Bagrodia A, Brugarolas J . Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15 year experience and lessons learned. BMC Urol. 2016; 16(1):43. PMC: 4952069. DOI: 10.1186/s12894-016-0157-3. View

Sun M, Ngo L, Genega E, Atkins M, Finn M, Rofsky N . Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings. Radiology. 2009; 250(3):793-802. DOI: 10.1148/radiol.2503080995. View

Psutka S, Boorjian S, Thompson R, Schmit G, Schmitz J, Bower T . Clinical and radiographic predictors of the need for inferior vena cava resection during nephrectomy for patients with renal cell carcinoma and caval tumour thrombus. BJU Int. 2014; 116(3):388-96. DOI: 10.1111/bju.13005. View

10.

Cooperberg M, Mallin K, Ritchey J, Villalta J, Carroll P, Kane C . Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol. 2008; 179(6):2131-5. DOI: 10.1016/j.juro.2008.01.097. View

11.

Lanzman R, Robson P, Sun M, Patel A, Mentore K, Wagner A . Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings. Radiology. 2012; 265(3):799-808. PMC: 3504320. DOI: 10.1148/radiol.12112260. View

12.

Gerety E, Lawrence E, Wason J, Yan H, Hilborne S, Buscombe J . Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design. Ann Oncol. 2015; 26(10):2113-8. PMC: 4576907. DOI: 10.1093/annonc/mdv289. View

13.

Bianchi M, Sun M, Jeldres C, Shariat S, Trinh Q, Briganti A . Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2011; 23(4):973-80. DOI: 10.1093/annonc/mdr362. View

14.

McDonald R, Probyn L, Poon I, Erler D, Brotherston D, Soliman H . Tumor Response After Stereotactic Body Radiation Therapy to Nonspine Bone Metastases: An Evaluation of Response Criteria. Int J Radiat Oncol Biol Phys. 2015; 93(4):879-81. DOI: 10.1016/j.ijrobp.2015.07.2288. View

15.

BOSNIAK M . The current radiological approach to renal cysts. Radiology. 1986; 158(1):1-10. DOI: 10.1148/radiology.158.1.3510019. View

16.

Hindman N, Hecht E, Bosniak M . Follow-up for Bosniak category 2F cystic renal lesions. Radiology. 2014; 272(3):757-66. DOI: 10.1148/radiol.14122908. View

17.

Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A . Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res. 2011; 17(18):6021-8. DOI: 10.1158/1078-0432.CCR-10-3309. View

18.

Chen W, Hill H, Christie A, Kim M, Holloman E, Pavia-Jimenez A . Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016; 539(7627):112-117. PMC: 5340502. DOI: 10.1038/nature19796. View

19.

Hoerner-Rieber J, Duma M, Blanck O, Hildebrandt G, Wittig A, Lohaus F . Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma-a multicenter analysis of the German working group "Stereotactic Radiotherapy". J Thorac Dis. 2017; 9(11):4512-4522. PMC: 5721071. DOI: 10.21037/jtd.2017.10.108. View

20.

Perez-Ordonez B, Hamed G, Campbell S, Erlandson R, Russo P, Gaudin P . Renal oncocytoma: a clinicopathologic study of 70 cases. Am J Surg Pathol. 1997; 21(8):871-83. DOI: 10.1097/00000478-199708000-00001. View